NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Pfizer
Conditions: Arthritis, Rheumatoid
Interventions: Tofacitinib, Tofacitinib
Countries: France
Regarding Tofacitinib, newly introduced on the market, few data on drug retention and no data on the factors predictive of Tofacitinib drug survival in patients with RA are available. Therefore, the primary objective of the DeFacTo study will be to identify the factors predictive of Tofacitinib drug survival in patients with RA. As secondary objectives, the impact of behavioural strategies on drug survival and other clinical parameters as well as Tofacitinib effectiveness and tolerability will be studied under real-life conditions of use in French patients with RA.
Sex: ALL
Age: 18 Years to —
Healthy volunteers: No
Study type: OBSERVATIONAL
Inclusion Criteria: * Patient 18 years of age or older * Patient in whom the diagnosis of moderate to severe active rheumatoid arthritis has been confirmed by a rheumatologist * Patient for whom the rheumatologist decides to initiate treatment with Tofacitinib * Patient informed of the study Exclusion Criteria: * Patient participating in a randomised clinical trial. * Patient presenting with a contraindication to prescription of Tofacitinib * Patients who are investigational site staff members or patients who are Pfizer employees directly involved in the conduct of the trial.
- Arras, France
- Aulnay-sous-Bois, France
- Aurillac, France
- Auxerre, France
- Berck, France
- Bobigny, France
- Bourg-en-Bresse, France
- Bourges, France
- Brest, France
- Brive-la-Gaillarde, France
- Bruges, France
- Cahors, France
- Caluire-et-Cuire, France
- Cannes, France
- Carcassonne, France
- Clermont-Ferrand, France
- Compiègne, France
- Créteil, France
- Dreux, France
- Juvisy-sur-Orge, France
- La Battie Vieille, France
- La Moutonne, France
- La Roche-sur-Yon, France
- Le Bouscat, France
- Le Bouscat, France
- Lille, France
- Lille, France
- Limoges, France
- Limoges, France
- Lyon, France
- + 36 more on CT.gov